NEW YORK, NY / ACCESS Newswire / December 18, 2025 / The conversation around cannabis reclassification, which was formalized through an executive order signed on Thursday, has focused heavily on policy and capital. Far less attention has been paid to operations. ...

Industry Overview - The marijuana industry is currently experiencing volatility, with potential changes in legislation under the Trump administration that may lead to the reclassification of marijuana for therapeutic use [2][3] - The cannabis sector is described as "the wild west," characterized by a lack of standardization and a diverse range of products from various suppliers, making it challenging for companies to achieve steady revenue growth [5][6] Company Insights - Company Tillray operates in the marijuana space, including CBD oils and beverages, and is noted as the fourth largest craft brew company in the U.S. [3] - Despite the potential for short-term opportunities due to legislative changes, Tillray faces significant challenges in standardizing its products and maintaining profitability [5][6] - Tillray's sales were approximately $830 million last year, with growth in the mid-single digits, but the company reported a loss of around $2 billion, which continues to pressure its equity [8] Market Dynamics - The cannabis ETF has seen a decline of over 85% from its peak, indicating a loss of enthusiasm in the market despite positive headlines regarding legalization [6] - Positive news in the marijuana sector often leads to short-term price increases, but these gains are not sustainable due to the industry's profitability challenges [7]

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs†or the "Company†), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell following President Trump's action to reschedule cannabis from a Schedule I to Schedule III substance under the Controlled Substances Act. "Today marks the most consequential moment in the history of U.S. cannabis. The decision to move cannabis from Schedule I to Schedule III will be a cultural turning point, ackn. ...

Verano’s active operations span 13 states, comprised of 158 dispensaries operating under the Zen Leaf™ and MÜV™ retail banners, and 15 cultivation and processing facilities with more than 1.1 million square feet of cultivation capacity CHICAGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, celebrates today’s historic announcement that President Donald Trump has issued an Executive Order directing the ...

Reclassification Eases Barriers to Research and Removes Punitive 280E Tax Burden  TALLAHASSEE, Fla., Dec. 18, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., applauds action taken by the Trump Administration to reclassify marijuana to Schedule III under the Controlled Substances Act. "This bold and historic direction from President Trump represents long overdue change and a major milestone in ...

U.S. President Donald Trump sits in the Oval Office to sign executive orders, at the White House in Washington, D.C., U.S., Dec. 18, 2025.President Donald Trump signed an executive order Thursday directing federal agencies to reclassify marijuana, loosening long-standing restrictions on the drug and marking the most consequential shift in U.S. cannabis policy in more than half a century.The order, once finalized by the Drug Enforcement Administration, moves cannabis out of Schedule I classification — the mo ...

Core Viewpoint - The reclassification of cannabis as a Schedule III drug by the Trump Administration is a significant reform that acknowledges its medical uses and low abuse potential, which will have long-term benefits for the cannabis industry [2]. Group 1: Impact of Reclassification - The reclassification is expected to accelerate accredited medical research into cannabis-derived medications, leading to increased consumer acceptance of cannabis as an alternative to opioids for chronic pain, sleep, anxiety, and other ailments [3]. - State-legal cannabis businesses will benefit from the removal of the IRS Section 280E tax penalty, allowing compliant operators like MariMed to be taxed similarly to other consumer packaged goods sectors, which will enhance profitability and free cash flow [4]. Group 2: Company Overview - MariMed Inc. is recognized as a leading multi-state cannabis operator, specializing in the development and management of advanced cultivation, production, and retail facilities [4]. - The company boasts an award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby's Baked™, Vibations™, InHouse™, and Nature's Heritage™, which are well-regarded by consumers nationwide [4].

Shares of Tilray Brands and other cannabis stocks are rising ahead of President Donald Trump's executive order signing ceremony. ...

Tilray and Canopy Growth shares are among big gainers Thursday. ...

Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") applauds the recent reports that US President Donald Trump and his administration are considering changes and the reclassification of federal cannabis policy in the USA, including potential rescheduling of cannabis from Schedule I to Schedule III. Schedule III drugs are considered to have a medical value and a lower abuse potential as defined by the Drug Enforcement Administration."Cannabis poli ...